Explore evolving first- and later-line treatments for EGFR exon 20 insertion NSCLC, including new targeted agents, chemo combos, and mutation-specific research.
Back
First-Line and Later-Line Strategies in EGFR Exon 20 Insertion–Mutated NSCLC
Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, and Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discuss how EGFR exon 20 insertions are identified in non–small cell lung cancer, how they weigh amivantamab plus chemotherapy against newer oral options such as sunvozertinib, zipalertinib, and firmonertinib in the first-line and later-line settings, and how central nervous system activity, toxicity, dosing, and sequencing shape treatment selection.
First-Line and Later-Line Strategies in EGFR Exon 20 Insertion–Mutated NSCLC
Episodes
All
All
Exon 20 EGFR insertions often go misreported, driving suboptimal inhibitor use; experts explain why NGS and liquid testing improve lung cancer treatment choices.
Advertisement
Advertisement
Trending on OncLive
1
Ivonescimab Plus Chemotherapy Represents a New SOC in First-Line Biliary Tract Cancer
2
CLARITY-Gastric01 Shows OS Benefit With Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastroesophageal Carcinoma
3
Dr Chase on the Potential Role of B7-H4–Targeted ADCs in Platinum-Resistant Ovarian Cancer
4
ESMO On Location Day 1
5